Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.
暂无分享,去创建一个
J. Humm | S. Larson | M. Morris | H. Scher | J. Carrasquillo | D. Danila | Simon-Peter Williams | B. Fine | P. Zanzonico | J. Fox | N. Pandit-Taskar | S. Cheal | J. O’Donoghue | S. Ruan | G. Ragupathi | V. Beylergil | Stephen E. Fleming | S. Lyashchenko
[1] M. Morris,et al. STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC). , 2015 .
[2] M. Morris,et al. A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). , 2014 .
[3] C. Kloft,et al. Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development , 2008, British Journal of Cancer.
[4] Gary A Ulaner,et al. First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer , 2017, The Journal of Nuclear Medicine.
[5] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.
[6] C. Higano,et al. A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). , 2013 .
[7] A. Scott,et al. A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen , 2007, Clinical Cancer Research.
[8] J A Parker,et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2001, Critical reviews in oncology/hematology.
[9] M. Loda,et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[10] S. Larson,et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. , 1991, Journal of the National Cancer Institute.
[11] Ronald Boellaard,et al. Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients , 2009, Journal of Nuclear Medicine.
[12] S. Kanner,et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. , 2007, Cancer research.
[13] Serge K. Lyashchenko,et al. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody , 2019, The Journal of Nuclear Medicine.
[14] R. Boellaard,et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer , 2015, Oncotarget.
[15] J. T. Trindade Filho,et al. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma , 2013, Histopathology.
[16] R. Boellaard,et al. Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer , 2014, EJNMMI Research.
[17] Johan R de Jong,et al. Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging , 2009, Journal of Nuclear Medicine.
[18] R. Boellaard,et al. Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients , 2006, Clinical Cancer Research.
[19] R. Pleijhuis,et al. 89Zr-Bevacizumab PET Imaging in Primary Breast Cancer , 2012, The Journal of Nuclear Medicine.
[20] F. Theil,et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. , 2011, Bioconjugate chemistry.
[21] C. Stroebel,et al. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. , 1969, Blood.
[22] Steven M. Larson,et al. Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.
[23] W. Weichert,et al. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding , 2017, The Journal of Nuclear Medicine.
[24] R. Hubert,et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Larson,et al. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[26] C Cobelli,et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. , 1998, Metabolism: clinical and experimental.
[27] P. Jurek,et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.
[28] Serge K. Lyashchenko,et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[29] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[30] S. Slovin. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen , 2005, Expert opinion on therapeutic targets.
[31] W. Brenner,et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.
[32] Jason S. Lewis,et al. Annotating STEAP1 Regulation in Prostate Cancer with 89Zr Immuno-PET , 2014, The Journal of Nuclear Medicine.
[33] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[34] J. Vose,et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Larson,et al. Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.
[36] B. Klein,et al. STEAP1 is overexpressed in cancers: a promising therapeutic target. , 2012, Biochemical and biophysical research communications.
[37] Danny F. Martinez,et al. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer , 2015, Clinical Cancer Research.
[38] C. Santos,et al. STEAP Proteins: From Structure to Applications in Cancer Therapy , 2012, Molecular Cancer Research.
[39] J. Humm,et al. 124I-huA33 Antibody PET of Colorectal Cancer , 2011, The Journal of Nuclear Medicine.
[40] Steven P. Larson,et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] N. Ibrahim,et al. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer , 2010, British Journal of Cancer.
[42] R. Hauke,et al. Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial , 2011, Clinical Cancer Research.
[43] Valerie A Longo,et al. Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab , 2010, PloS one.